Shares of Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Get Free Report) shot up 22% on Friday . The company traded as high as $0.74 and last traded at $0.72. 125,477 shares changed hands during mid-day trading, an increase of 309% from the average session volume of 30,690 shares. The stock had previously closed at $0.59.
Matinas Biopharma Trading Up 22.0%
The firm has a market capitalization of $4.62 million, a P/E ratio of -0.21 and a beta of 1.28. The stock has a 50 day simple moving average of $0.73 and a 200-day simple moving average of $1.24.
Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter.
About Matinas Biopharma
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
Featured Articles
- Five stocks we like better than Matinas Biopharma
- How a Family Trust May Be Able To Help Preserve Your Wealth
- Do not delete, read immediately
- Your Signature Is Missing – Act Before It’s Too Late
- The $100 Trillion AI Story No One Is Telling You
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
